Trial Profile
A second Phase II trial of Xanamem in the treatment of Diabetes Cognitive Impairment
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 28 Apr 2017
Price :
$35
*
At a glance
- Drugs UE 2343 (Primary)
- Indications Cognition disorders
- Focus Therapeutic Use
- 28 Apr 2017 New trial record
- 26 Apr 2017 According to an Actinogen Medical media release, this trial has been proposed by the University of Edinburgh and is expected to begin in 2017.